Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

Sparrow Pharmaceuticals Presents New Clinical Trial Data Analyses on HSD-1 Inhibitor SPI-62 at the 24th European Congress of Endocrinology


Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of glucocorticoid excess, today presented new pharmacological data during a poster session and a Rapid Communications session titled, "HPA axis modulation by a potent inhibitor indicates 11?-hydroxysteroid dehydrogenase type 1 (HSD-1) is a main source of cortisol that can bind intracellular receptors" at the 24th European Congress of Endocrinology (ECE 2022). Sparrow scientists examined the steroid hormone changes after administration of its lead therapeutic candidate, SPI-62, an HSD-1 inhibitor, to healthy adults.

"Normalized urinary free cortisol, or UFC, is a standard therapeutic target for patients with Cushing's syndrome," said David A. Katz, Ph.D., CSO at Sparrow Pharmaceuticals, "But that biomarker doesn't measure the cortisol that can access intracellular receptors and cause symptoms. UFC normalization has been shown not to correlate with clinical endpoints in patients with Cushing's syndrome. Many patients with autonomous cortisol secretion have normal UFC, yet substantial cortisol morbidity. As we conduct clinical trials for patients with those diseases, we're in search of better ways to measure the cortisol that makes patients ill."

The study analyzed historical clinical trial data to better characterize how SPI-62 impacts cortisol levels and the body's homeostatic response to those changes.

Conclusions of the study include:

HSD-1 converts cortisone to cortisol in tissues in which cortisol excess is associated with morbidity including liver, adipose, bone, and brain. SPI-62 is a potent HSD-1 inhibitor in clinical development for treatment of Cushing's syndrome and autonomous cortisol secretion, and as adjunctive therapy to prednisolone in polymyalgia rheumatica. In Phase 1 clinical trials SPI-62 was generally well tolerated and associated with maximal liver and brain HSD-1 inhibition.

To register and view the abstracts, visit ECE's website here.

To learn more about Sparrow Pharmaceuticals and its clinical pipeline, visit the website at www.sparrowpharma.com.

About Sparrow Pharmaceuticals

Sparrow Pharmaceuticals was founded to spare patients the ravages of steroids. Leveraging underappreciated scientific insights into corticosteroid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism, and to revolutionize the treatment of autoimmune and inflammatory conditions. Its lead product, SPI-62, is an oral, small molecule, novel therapeutic treatment designed to target the source of active intracellular corticosteroids in key tissues.


These press releases may also interest you

at 12:15
ResBiotic Nutrition, Inc. (ResBiotic), the pioneering physician-developed pre/probiotic wellness scale-up, proudly announces the appointments of Stefany Nieto as Vice President of Operations and Brittany Zenner as Director of Marketing. Nieto is a...

at 12:06
Maid Sailors Cleaning Service has joined forces with Cleaning for a Reason, a non-profit organization offering free house cleaning services to cancer patients across the United States and Canada....

at 12:05
Terragia Biofuel, a technology startup aiming to drive the next generation of biofuels, today announced it has raised a $6 million seed round led by Engine Ventures and Energy Impact Partners (EIP). The company will use the capital to commercialize...

at 12:05
Float, the marketplace moving all the care that doesn't need a hospital to the home, today announced $10 million in Series A funding led by Canvas Ventures, whose General Partner Mike Ghaffary has joined Float's board, with participation from Wave...

at 12:00
V-Wave today announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American College of Cardiology's (ACC) Annual Scientific Session & Expo taking place April 6-8 in Atlanta. RELIEVE-HF is a randomized, double-blind,...

at 12:00
Critical Path Institute's (C-Path) Duchenne Regulatory Science Consortium (D-RSC) is excited to announce the launch of a groundbreaking model-based Clinical Trial Simulator (CTS), specifically designed to improve design of efficacy studies for...



News published on and distributed by: